Nuo Therapeutics, Inc.

For the period ended Dec 31, 2024. Filed Apr 1, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Apr 1, 2025

AURXStored price and day change unavailable

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets

Nuo Therapeutics, Inc.

Consolidated Balance Sheets

	December 31,	December 31,
	2024	2023
Assets
Current assets
Cash	$283,714	$928,681
Accounts receivable, net	248,205	250,703
Inventory, net	150,442	209,589
Prepaid expenses and other current assets	159,185	174,471
Total current assets	841,546	1,563,444
Property and equipment, net	177,022	45,082
Operating lease right of use assets	170,940	269,354
Total assets	$1,189,508	$1,877,880
Liabilities and Stockholders' Equity
Current liabilities
Accounts payable	$219,190	$394,518
Accrued expenses	292,400	188,622
Current portion of operating lease liabilities	66,861	91,387
Total current liabilities	578,451	674,527
Non-current portion of operating lease liabilities	97,345	164,205
Total liabilities	675,796	838,732
Commitments and contingencies (Note 9)
Stockholders' Equity
Common stock; $0.0001 par value; 100,000,000 shares authorized; 46,816,114 and 44,241,516 shares issued and outstanding at December 31, 2024 and 2023, respectively	4,682	4,424
Additional paid-in capital	32,768,976	30,970,965
Accumulated deficit	(32,259,946)	(29,936,241)
Total stockholders' equity	513,712	1,039,148
Total liabilities and stockholders' equity	$1,189,508	$1,877,880

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.